Dr. Andriole discusses promise of 18F-fluciclovine for managing biochemically recurrent prostate cancer

Video

“For most men, we can identify the specific site or sites of recurrence, and thereby use a more directed therapy that specifically targets the abnormal sites,” says Gerald L. Andriole, MD.

In this video, Gerald L. Andriole, MD, discusses the background and findings of the study, “Impact of 18F-Fluciclovine PET/CT on plans for ADT in patients with biochemical recurrence of prostate cancer; data analysis from two prospective clinical trials,” presented recently at the 2021 Society of Urologic Oncology Annual Meeting. Andriole is a Robert Killian Royce distinguished professor of urologic surgery at the Washington University School of Medicine in St. Louis, Missouri.

Related Videos
3d rendered illustration of kidney cancer | Image Credit: © SciePro - stock.adobe.com
Bottle of white pills | Image Credit: © leighannef - stock.adobe.com
Illustration of AI | Image Credit: © Tierney - stock.adobe.com
DNA illustration | Image Credit: © BillionPhotos.com - stock.adobe.com
Mara R. Holton, MD, answers a question during a Zoom video interview
3d rendered illustration of bladder cancer | Image Credit: © SciePro - stock.adobe.com
© 2023 MJH Life Sciences

All rights reserved.